Overspending driven by oversized single dose vials of cancer drugs

Peter Brian Bach · Rena M. Conti · Raymond J. Muller · Geoffrey C. Schnorr · Leonard B. Saltz

155 citations0/0 files storedBMJ

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Healthcare cost, quality, practices Economic and Financial Impacts of Cancer

Abstract

Peter B Bach and colleagues call for an end to contradictory regulatory standards in the US that allow drug manufacturers to boost profits by producing single dose vials containing quantities that increase leftover drug

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 155 citations exist upstream.

Cited by

2017A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer 2024Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis 2020Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value 2021Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments 2017Making individualized drugs a reality 2018Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma 2021What cancer research makes the news? A quantitative analysis of online news stories that mention cancer studies

Imported from OpenAlex (CC0) — nothing here is generated.